Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients both sexes~* Age between 30 and 60 years~* Metabolic Syndrome according to the IDF criteria:~* Waist circumference Man ≥90 cm, Woman ≥80 cm; and two of the following criteria:~* High density lipoprotein Man ≤40 mg/dL, Woman ≤50 mg/dL;~* Fasting glucose ≥100 mg/dL;~* Triglycerides ≥150 mg/dL;~* Blood pressure ≥130/85 mmHg~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to ursolic acid o calcined magnesia~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Previous treatment for the metabolic syndrome components~* Body Mass Index ≥39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL~* Low density lipoprotein (c-LDL) ≥190 mg/dL~* Blood Pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ursolic acid (Type: EXPERIMENTAL): Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).